Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）
Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
In this trial, we will treat relapsed PCNSL with temozolomide, pemetrexed. Our objective was
to assess our treatment strategies' availability based on response rates, progression-free
survival (PFS), median PFS, and toxicity.